Some useful links to MPN information resources, guidelines and detailed research articles are provided below.
Essential thrombocythemia (ET) specific information
Polycythemia Vera (PV) specific information
Myelofibrosis (MF) specific information
Myelofibrosis Stem Cell Transplant information
Blood tests, bone marrow biopsies and MPN morphology
Pediatric and Young Adult MPNs
- Australian Optimal Care Pathways for Myeloproliferative Neoplasms, May 2024
- US National Comprehensive Cancer Network (NCCN) Guidelines for Patients: Myeloproliferative Neoplasms – 2024
- Myeloproliferative neoplasms: Classifications and an approach to diagnosis, Australian Journal of General Practice, 2021
- Biology and therapeutic targeting of molecular mechanisms in MPNs, Blood, 2023
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data, Blood, 2022
- Myeloproliferative neoplasms unclassifiable: how I manage – practical approaches for 2022 and beyond, BJH, 2022
- Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms , 2020
- Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights, International Journal of Molecular Sciences, 2024
- Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology, Annals of Hematology, 2024
- Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms, Hamostaseologie, 2023
- Splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies, Critical review, AJH, 2023
- Splanchnic vein thrombosis – a national retrospective cohort study of MPN-SVT, courtesy of MPN Hub, 2022
- Myeloproliferative neoplasms – blurring the lines between cancer and chronic inflammatory disorder, 2023
- New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms, Hemasphere, 2021
- Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2– and CALR-mutated essential thrombocythemia, (Research article) AJH, 2024
- Myeloproliferative neoplasms in the adolescent and young adult population: a comprehensive review of the literature, 2024
- Childbirth rates in women with myeloproliferative neoplasms, Leukemia, 2024
- Maternal and fetal risks in pregnancy with MPN: 2023. Courtesy of MPN Hub
- What are the key considerations in managing pregnancy in myeloproliferative neoplasms, Elisabetta Abruzzese – courtesy of MPN Hub, 2023
- Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET, Hemasphere, Letter, 2023
- Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms—a nationwide population-based study of 342 pregnancies in Sweden, 2022
- Best practice recommendations for the management of MPN in pregnant patients, courtesy of MPN Hub, 2021
(Please note that these are not Australian guidelines and local Australian practices may differ.) - Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations, AJH, 2020
- How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy, BJH 2020
Essential thrombocythemia (ET) specific information
- Essential thrombocythemia: 2024 update on diagnosis, risk stratification and management, AJH, 2024
- Site specific venous thrombosis in ET: impact on subsequent vascular events and survival, ‘Journal of thrombosis and haemostasis’, 2022
- Essential thrombocythemia: challenges in clinical practice and future prospects, Blood 2023
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk stratification and management, USA
- Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet, 2021
- MPL-mutated essential thrombocythemia: a morphologic reappraisal, Blood Cancer Journal, 2018
- Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis, Platelets, 2022
- Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients, AJH, Research article, 2014
Polycythemia Vera (PV) specific information
- Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL, Blood, 2024
- Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management, American Journal of Hematology, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera, Review, Vascular Health and Risk Management, 2023
- JAK2V617F allele burden in polycythemia vera: burden of proof, Blood, 2023
- Diagnostics and risk stratification for patients with polycythemia vera, Expert Roundtable Review, 2023
- Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b, Leukemia, 2022
- Appropriate management of polycythaemia vera with cytoreductive drug therapy – European LeukemiaNet recommendations, 2021
- Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival Leukemia’, 2021
- A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline, 2019
- A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis – A British Society for Haematology Guideline, 2018
- Basis of Hematocrit Treatment Guideline for PV: Cardiovascular Events and the Intensity of Treatment in Polycythaemia Vera, ‘NEJM’, 2013
Myelofibrosis (MF) specific information
- Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group, Letter, Leukemia, 2024
- Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib, Letter to Blood, 2024
- Management of Patients with Early Myelofibrosis: A Discussion of Best Practices, Review paper, 2024
- Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group, Leukemia, 2024
- Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline, BJH 2023
- The management of myelofibrosis: A British Society for Haematology Guideline, Companion Guideline, BJH, 2023
- Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology (myelofibrosis focus)
- Myelofibrosis, Blood, 2023
- Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management, AJH, 2023
- Blast phase MPN: contemporary review and 2024 treatment algorithm, Nature – Blood Cancer Journal, 2023
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety, Journal of Hematology and Oncology, 2023
- Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy, Leukemia and Lymphoma, 2023
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia, Journal of Hematology and Oncology, 2022
- A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study, Therapeutic Advances in Hematology, 2022
Myelofibrosis Stem Cell Transplant information
- Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group, The Lancet Hematology. 2024
- How I treat transplant-eligible patients with myelofibrosis, Blood, 2023
- Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis, Haematologica, 2023
- Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial, Blood Advances, 2023
- Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms:
A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, AJH, 2023 - Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis, AJH, 2022
- MPN Research Foundation (USA) – patient specific information about stem cell transplants and timing
- Survival following allogeneic transplant in patients with myelofibrosis
- FACT SHEETS are provided on all the main treatments available for Australian MPN patients. These are available in several languages.
- Articles on MPN treatment – this link includes:
– a conversation with an MPN specialist about how interferons work in MPN patients,
– comparison studies of interferon and hydroxyurea,
– efficacy and safety of myelofibrosis treatments,
– clinical trial outcomes from Australia and overseas, and
– new developments for myelofibrosis treatments.
Blood tests, bone marrow biopsies and MPN morphology
- Understand your blood tests
- Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: data from the ALLG MPN01 registry, Pathology Journal, RCPA, 2023
- Morphology of myeloproliferative neoplasms, Int J Lab Hematol. 2023
- Life histories of myeloproliferative neoplasms inferred from phylogenies, Nature, 2022
- Genetic basis and molecular profiling in myeloproliferative neoplasms, Blood, 2023
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms, NEJM, 2018
- Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population, Blood, 2019
- ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera, Blood Advances (letter), 2022
- Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
- Genetics Home Reference – Your Guide to Understanding Genetic Conditions
- ET https://ghr.nlm.nih.gov/condition/essential-thrombocythemia
- PV https://ghr.nlm.nih.gov/condition/polycythemia-vera#resources
- MF https://ghr.nlm.nih.gov/condition/primary-myelofibrosis
Links to information on various genetic mutations
- JAK2 https://ghr.nlm.nih.gov/gene/JAK2
- CALR https://ghr.nlm.nih.gov/gene/CALR
- MPL https://ghr.nlm.nih.gov/gene/MPL#resources
- TET2 https://ghr.nlm.nih.gov/gene/TET2#conditions
Pediatric and Young Adult MPNs
- Myeloproliferative neoplasms in the adolescent and young adult population: a comprehensive review of the literature, 2024
- Weill Cornell Medicine Pediatric Myeloproliferative Neoplasm Program
- Characterization of myeloproliferative neoplasms in the paediatric and young adult population, BJH 2023
- Clinical features associated with thrombotic events in children with myeloproliferative neoplasms 2022
- Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs, Blood Advances, 2022
